From my standpoint, the area of protein homeostasis — learning the rules of how protein synthesis is balanced with protein degradation — is one of the most exciting oncology areas to be in. If you look back to the early to mid 1980s, when I was at the National Cancer Institute, the oncology research that was most exciting was the area of protein kinases, and that is how I see protein homeostasis today. The area is rich in targets, and we are going to see many different drugs come out of this area, not only for cancer but many types of diseases (such as neurodegenerative diseases). With advances in proteomics, particularly in the mass spectrometry area, we are starting to get the kind of perspective that in the late 1990s we could only get for genomics. Now we have the scientific expertise at Millennium to be at the forefront of that research and to rapidly translate it into novel medicines, so it is quite exciting.